SEC Tracker
Get the app

Gossamer Bio GOSS

Gossamer Bio reports Q3 2026 financial results

Gossamer Bio (GOSS) filed an 8-K with the SEC on Nov 10, 2026, 4:51 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities totaled $51.2 million as of September 30, 2026
  2. Revenue from contracts with collaborators was $38.4 million for the quarter ended September 30, 2026
  3. Net loss for the quarter was $48.1 million, or $7.36 per share
  4. Seralutinib NDA submitted to the U.S. FDA in September 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Gossamer Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.